Get the Stockscreener App
20.71
3.58%
0.715
Faeth Therapeutics Inc stock is traded at $20.71, with a volume of 154.01K.
It is up +3.58% in the last 24 hours and down -41.43% over the past month.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
See More
Previous Close:
$20.00
Open:
$19.9
24h Volume:
154.01K
Relative Volume:
0.50
Market Cap:
$535.28M
Revenue:
Net Income/Loss:
$-184.46M
P/E Ratio:
-0.1451
EPS:
-142.7277
Net Cash Flow:
$-24.11M
1W Performance:
-19.11%
1M Performance:
-41.43%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$19.90
$21.39
1-Week Range:
$19.85
$26.64
52-Week Range:
$13.43
$42.14
Faeth Therapeutics Inc Stock (FTH) Company Profile
Name
Faeth Therapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
20.71 | 535.28M | 0 | -184.46M | -24.11M | -142.73 |
VRTX
Vertex Pharmaceuticals Inc
|
507.88 | 128.73B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
239.04 | 95.43B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.20 | 82.28B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.25 | 53.66B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Faeth Therapeutics Inc Stock (FTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-26 | Initiated | Guggenheim | Buy |
| Sep-09-26 | Initiated | TD Cowen | Buy |
| Aug-21-26 | Initiated | Needham | Buy |
| Jul-31-26 | Initiated | Raymond James | Outperform |
| Jul-28-26 | Initiated | Oppenheimer | Outperform |
| Jul-20-26 | Initiated | Citizens | Mkt Outperform |
| Jun-26-26 | Initiated | Robert W. Baird | Outperform |
| Jun-22-26 | Initiated | H.C. Wainwright | Buy |
| Jun-11-26 | Initiated | BTIG Research | Buy |
| May-29-26 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-26 | Initiated | Citigroup | Buy |
| Apr-20-26 | Initiated | Leerink Partners | Outperform |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Faeth Therapeutics Inc Stock (FTH) Latest News
Faeth Therapeutics Director Karen H. Vousden Granted 25,000 Stock Options - Kalkine Media
Faeth Therapeutics (FTH) awards 25,000 stock options to director - Stock Titan
Faeth Therapeutics at Cantor Fitzgerald conference: oral PI3K push By Investing.com - Investing.com Canada
A booming business on Wall Street would love more biotechs to quietly die - BioPharma Dive
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
FTH Initiated Coverage by TD Cowen -- Rating Set to Buy - GuruFocus
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com India
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com Canada
TD Cowen initiates Faeth Therapeutics stock with buy rating By Investing.com - Investing.com UK
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 - BioSpace
Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026 - Yahoo Finance
About 80% of endometrial tumors have a pathway alteration. Faeth will discuss PIKTOR. - Stock Titan
Faeth Therapeutics stock hits 52-week high at 40.89 USD By Investing.com - Investing.com Australia
Faeth Therapeutics stock hits 52-week high at 40.89 USD - investing.com
Faeth Therapeutics stock hits 52-week high at 40.89 USD By Investing.com - Investing.com Canada
Bullish Faeth Therapeutics Insiders Rewarded As Their Investment Rises To US$1.94m - simplywall.st
Insiders of Faeth Therapeutics Getting Good Value On Their US$1.19m Investment - Moomoo
Biotech Stocks At 52-Week HighsOABI +13%, FRNM, EXEL, FTH, LFST - RTTNews
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - Eastern Progress
Faeth Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire
Faeth Therapeutics to Participate in Upcoming September Investor Conferences - Yahoo Finance Singapore
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Faeth Therapeutics (FTH) Grants Stock Options to New Hires Amid Unprofitable Growth Phase - GuruFocus
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Capital expenditures of Faeth Therapeutics, Inc. – NASDAQ:FTH - TradingView
Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know - Yahoo Finance
FAETH THERAPEUTICS, INC : NEEDHAM INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $56 - Bitget
Needham initiates Faeth Therapeutics stock with buy rating on cancer drug potential - Investing.com Canada
FTH Initiates Coverage On by Needham -- Buy Rating with $56 Pric - GuruFocus
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - sahmcapital.com
Khosla Ventures Seed Associates D, Llc Net Worth (2026) - GuruFocus
Why is Faeth Therapeutics stock surging today? By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - BioSpace
FDA grants fast track status to Faeth’s endometrial cancer drug - Investing.com
Faeth Therapeutics (FTH) Gains FDA Fast Track for Endometrial Ca - GuruFocus
FDA grants fast track status to Faeth’s endometrial cancer drug By Investing.com - Investing.com Canada
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - Yahoo Finance
Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer - Business Wire
FTH: Faeth Therapeutics, Inc.Insider Transations - Zacks Investment Research
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH) investor Trails Edge reports 2.0% beneficial stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH): Khosla Ventures group discloses 10.2% ownership stake - Stock Titan
Faeth Therapeutics, Inc. (NASDAQ: FTH) Share Price, FTH Stock News, FTH Share Price & Updates - kalkine.ca
PR News | On the Move: Finn Names Flach PartnerFri., Aug. 14, 2026 - O'Dwyer's PR
Faeth Therapeutics (FTH) investor group reports 0% ownership in amended 13G - Stock Titan
Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments - TradingView
Faeth Therapeutics Adds Senior Leaders Ahead of PIKTOR Clinical Milestones - citybiz
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments - BioSpace
Faeth Therapeutics names two senior vice presidents - Investing.com
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments - Yahoo Finance
Faeth Therapeutics Inc Stock (FTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Faeth Therapeutics Inc Stock (FTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STEPHENSON BRIAN C | Chief Financial Officer |
Jul 01 '26 |
Buy |
23.50 |
5,000 |
117,492 |
46,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 30 '26 |
Buy |
24.25 |
7,803 |
189,240 |
41,688 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 29 '26 |
Buy |
23.34 |
831 |
19,396 |
33,885 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 26 '26 |
Buy |
24.95 |
6,250 |
155,908 |
33,054 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 24 '26 |
Buy |
26.13 |
9,391 |
245,360 |
26,804 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 23 '26 |
Buy |
24.36 |
9,230 |
224,806 |
17,413 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Buy |
19.76 |
2,806 |
55,447 |
764,234 |
| Parikh Anand Kiran | President and CEO |
Jun 22 '26 |
Option Exercise |
1.16 |
53,465 |
62,019 |
817,699 |
| STEPHENSON BRIAN C | Chief Financial Officer |
Jun 22 '26 |
Buy |
22.13 |
8,183 |
181,115 |
8,183 |
| Cambrian BioPharma Inc | 10% Owner |
Jun 01 '26 |
Sale |
20.02 |
25,000 |
500,543 |
130,142 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):